Inclusion Criteria:

          -  Pathologic diagnosis (cell samples, biopsy, brushing, surgical sample) of
             adenocarcinoma of the pancreas. Cancer from the Ampullae of Vater is also eligible.
             The tissue sample can be from a metastatic location, like a lymph node.

          -  Metastatic or node positive disease

          -  One cancer site, that did not receive radiation therapy, that is at least 1 cm in size
             when looking at it by CT scan (CAT scan)

          -  Recommended to receive gemcitabine and nab-paclitaxel

          -  Failed initial therapy or be ineligible for definitive curative therapy (e.g.,
             surgical excision, radiation therapy)

          -  A platelet count of at least 100,000 cells per mL

          -  A creatinine level of less than 1 1/2 times the upper limit of normal for the local
             lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)

          -  Not pregnant

          -  Commit to using birth control during the study (all participants)

        Exclusion Criteria:

          -  Prior chemotherapy to treat the metastatic disease

          -  Other therapy (including radiation) within the past 4 weeks

          -  Side effects from prior therapies that are still deemed moderate to severe by a
             physician

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Patients actively receiving insulin or who are currently recommended to receive
             insulin by a doctor

          -  Patients requiring daily finger-stick blood glucose measurements

          -  Patients who are on the following drugs and cannot have a substitution (or who decline
             the substitution):

               -  warfarin

               -  flecainide

               -  methadone

               -  amphetamines

               -  quinidine

               -  chlorpropamide

          -  An active cancer, other than the pancreatic cancer, that requires treatment.

          -  Enrolled in another therapeutic clinical trial

          -  Uncontrolled, intercurrent illness

          -  HIV positive individuals undergoing therapy due to known drug:drug interaction between
             antiretroviral drugs and high-dose ascorbate therapy

          -  Women who are nursing